These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31720816)

  • 1. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
    Jin C; Zheng H; Zhan M; Wen F; Xu T
    Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
    Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
    Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
    Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
    BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    Hong S; Zhang Y; Yu G; Peng P; Peng J; Jia J; Wu X; Huang Y; Yang Y; Lin Q; Xi X; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C; Fang W; Zhang L
    J Clin Oncol; 2021 Oct; 39(29):3273-3282. PubMed ID: 34379443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Tian K; Han J; Wang Z; Chen J
    Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
    Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024; 27(sup3):9-23. PubMed ID: 39016811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
    Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
    Kong XY; Lu JX; Yu XW; Zhang J; Xu QL; Zhang RJ; Mi JL; Liao SF; Fan JF; Qin XL; Yao DC; Tang HY; Jiang W
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):155-161. PubMed ID: 31087135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
    Yang J; Han J; He J; Duan B; Gou Q; Ai P; Liu L; Li Y; Ren K; Wang F; Yao M; Chen N
    Front Oncol; 2020; 10():594756. PubMed ID: 33425747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
    Phippen NT; Leath CA; Chino JP; Jewell EL; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2012 Nov; 127(2):267-72. PubMed ID: 22892361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
    Roth JA; Carlson JJ
    J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
    Kharat AA; Nelson R; Au T; Biskupiak J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.